How did Senores' regulated markets perform in Q1?

Regulated markets (US and Canada) grew 42% YoY, outpacing total revenue growth. This segment has been the primary driver of the company's recent expansion.

Was the profit growth stronger than revenue growth?

Yes, net profit grew 44% against 36% revenue growth, suggesting slight operating leverage. However, the absolute numbers are in line with the trend seen in the previous quarter.

Does this filing indicate any change in business outlook?

No. The analyst rationale indicates results were consistent with guidance. The appointment of Anjali Shah as senior management is administrative and doesn't alter the company's strategic direction.

How does Q1 FY27 compare with the immediately preceding quarter (Q4 FY26)?

The filing does not provide Q4 FY26 figures. The comparison is only against Q1 FY26. Sequential trends are not available from this filing.

Earnings · Pharmaceuticals · Mid cap

Senores Q1 profit surges 44% on regulated markets growth

Revenue climbs 36% to ₹180 crore, but the numbers were well telegraphed in guidance.

— 5 earlier stories on Senores Pharmaceuticals Ltd. →

SENORES By Tipsheet Editorial 27 Jul 2026 · 3:25 PM IST Verify on BSE · NSE

Mkt cap₹5,840 cr

P/E50.62×

ROE7.45%

Debt / eq.0.39

44% Net profit growth YoY to ₹30 cr in Q1 FY27

What's new

Revenue up 36% YoY to ₹180 cr, driven by regulated markets (+42%) and emerging markets (+30%).
Net profit rose 44% to ₹30 cr, consistent with prior quarters' strength.
Board approved Anjali Shah as senior management personnel from July 27, 2026.

Why this matters

The numbers continue a strong growth trend but are well within the company's own guidance. With a trailing P/E of 50.6, the stock already prices in this trajectory. The filing adds no new catalyst.

What we're watching

Whether the regulated markets growth rate sustains above 40% through FY27.
Any update on the US specialty pipeline that could extend the earnings premium.
The pace of margin changes as revenue scales.

The full read

Senores delivered another quarter of solid execution. Revenue hit ₹180 crore, up 36% YoY. Net profit of ₹30 crore rose 44%. Regulated markets led at 42% growth. Hardly a surprise. All these numbers were well guided, and the market has already paid for this trajectory with a 50.6x trailing P/E that leaves little room for error. The open question is not this quarter's beat but whether the pipeline can sustain the premium that Senores commands in a sector where guidance rarely undershoots.

Questions answered

How did Senores' regulated markets perform in Q1?: Regulated markets (US and Canada) grew 42% YoY, outpacing total revenue growth. This segment has been the primary driver of the company's recent expansion.
Was the profit growth stronger than revenue growth?: Yes, net profit grew 44% against 36% revenue growth, suggesting slight operating leverage. However, the absolute numbers are in line with the trend seen in the previous quarter.
Does this filing indicate any change in business outlook?: No. The analyst rationale indicates results were consistent with guidance. The appointment of Anjali Shah as senior management is administrative and doesn't alter the company's strategic direction.
How does Q1 FY27 compare with the immediately preceding quarter (Q4 FY26)?: The filing does not provide Q4 FY26 figures. The comparison is only against Q1 FY26. Sequential trends are not available from this filing.

Mentioned: Anjali Shah · ₹180 cr revenue · 42% regulated markets growth

Primary source BSE · NSE

An independent reading of the company's own disclosure — the primary filing above is the final word.

Story so far

All notes on SENORES →

27 Jul 2026 · 3:25 PM IST Senores Q1 profit surges 44% on regulated markets growth
today Senores Pharma targets 50-60% PAT growth after Q1 beat
today Senores delays Atlanta plant, redirects ₹65 cr of IPO funds
today Senores Q1 revenue jumps 36% to ₹180 cr, profit up 56%
today Senores Q1 profit rises 56% on regulated markets growth